Alexion Pharmaceuticals Inc

Find Ratings Reports
ALXN : NASDAQ : Health Care
$131.07 | %
Today's Range: 0.0 - 0.0
Avg. Daily Volume: 3158000.0
07/26/17 - 4:00 PM ET

Financial Analysis


ALEXION PHARMACEUTICALS INC's gross profit margin for the first quarter of its fiscal year 2017 is essentially unchanged when compared to the same period a year ago. The company managed to grow both sales and net income at a faster pace than the average competitor in its industry this quarter as compared to the same quarter a year ago. ALEXION PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 2.54 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.

During the same period, stockholders' equity ("net worth") has increased by 9.84% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY17 Q1 FY16
Net Sales ($mil)870.0701.04
EBITDA ($mil)341.0250.42
EBIT ($mil)242.0153.64
Net Income ($mil)170.092.17


Balance Sheet Q1 FY17 Q1 FY16
Cash & Equiv. ($mil)1462.01027.55
Total Assets ($mil)13435.012802.45
Total Debt ($mil)3283.03421.1
Equity ($mil)8856.08062.28


Profitability Q1 FY17 Q1 FY16
Gross Profit Margin94.4894.04
EBITDA Margin39.1935.72
Operating Margin27.8221.92
Sales Turnover0.240.21
Return on Assets3.541.13
Return on Equity5.381.8
Debt Q1 FY17 Q1 FY16
Current Ratio3.273.52
Debt/Capital0.270.3
Interest Expense24.023.89
Interest Coverage10.086.43


Share Data Q1 FY17 Q1 FY16
Shares outstanding (mil)224.0224.2
Div / share0.00.0
EPS0.750.41
Book value / share39.5435.96
Institutional Own % n/a n/a
Avg Daily Volume3157509.01917712.0

Valuation


BUY. ALEXION PHARMACEUTICALS INC's P/E ratio indicates a significant premium compared to an average of 44.01 for the Biotechnology industry and a significant premium compared to the S&P 500 average of 24.66. To use another comparison, its price-to-book ratio of 3.28 indicates valuation on par with the S&P 500 average of 3.07 and a significant discount versus the industry average of 11.44. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
ALXN 61.52 Peers 44.01   ALXN 23.71 Peers 43.69

Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.

ALXN is trading at a significant premium to its peers.

 

Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

ALXN is trading at a significant discount to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
ALXN 19.64 Peers 27.93   ALXN 0.31 Peers 0.55

Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations.

ALXN is trading at a discount to its peers.

 

Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

ALXN trades at a significant discount to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
ALXN 3.28 Peers 11.44   ALXN 193.05 Peers -7.96

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

ALXN is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

ALXN is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
ALXN 8.94 Peers 190.63   ALXN 20.26 Peers 434.91

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

ALXN is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

ALXN significantly trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades